# US Peptic Ulcer Drugs Market > US Peptic Ulcer Drugs Market Research Report By Pharmacological Class (Proton Pump Inhibitors (PPIs), Anti-histamines, H2 Antagonists, Antacids, Others) and By Clinical (Gastric Ulcers, Duodenal, Ulcer, Esophageal Ulcer) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.22% - **2024:** $ 1,130 Million - **2025:** $ 1,177.69 Million - **2035:** $ 1,780 Million - **Key Players:** Pfizer Inc (US), AstraZeneca PLC (GB), Boehringer Ingelheim GmbH (DE), Takeda Pharmaceutical Company Limited (JP), Novartis AG (CH), GlaxoSmithKline PLC (GB), Sanofi S.A. (FR), AbbVie Inc (US) **Report ID:** MRFR/Pharma/17953-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-peptic-ulcer-drugs-market-19500 --- ## Market Summary ## **US Peptic Ulcer Drugs Market Overview** As per MRFR analysis, the US Peptic Ulcer Drugs Market Size was estimated at 1.06 (USD Billion) in 2023. The US Peptic Ulcer Drugs Market Industry is expected to grow from 1.5(USD Billion) in 2024 to 2.5 (USD Billion) by 2035. The US Peptic Ulcer Drugs Market CAGR (growth rate) is expected to be around 4.753% during the forecast period (2025 - 2035). ### **Key US Peptic Ulcer Drugs Market Trends Highlighted** The US Peptic Ulcer Drugs Market is experiencing significant trends shaped by various factors. The increasing prevalence of peptic ulcers in the US, driven by lifestyle changes and rising stress levels, highlights the growing need for effective treatment options. Factors such as high consumption of nonsteroidal anti-inflammatory drugs (NSAIDs) and infection by Helicobacter pylori further propel the demand for ulcer medications. Additionally, the rise of gastrointestinal disorders has prompted pharmaceutical companies to focus on innovative drug development, showcasing a trend towards personalized medicine in the treatment of peptic ulcers. Opportunities to be explored within the US market include the development of over-the-counter (OTC) medications that offer accessible treatment options for patients. The shift in consumer preferences toward self-medication is creating room for pharmaceutical companies to introduce new products that are easy to obtain and use. Furthermore, advancements in drug delivery systems present a chance to enhance treatment efficacy and patient experience, as there is a growing interest in formulations that improve adherence. Recent trends also indicate a move towards integrating digital health solutions in managing peptic ulcer treatment. Telehealth services are becoming increasingly popular, allowing patients to access healthcare professionals for advice and prescriptions conveniently. This trend is particularly relevant in the US, where accessibility and convenience are high priorities for patients. Overall, the confluence of rising disease incidence, innovative treatment options, and changing consumer behavior signals a dynamic landscape for the US Peptic Ulcer Drugs Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **US Peptic Ulcer Drugs Market Drivers** #### **Increasing Prevalence of Helicobacter Pylori Infection** The increase in Helicobacter Pylori infections is a significant driver of growth in the US [Peptic Ulcer Drugs Market](../../../reports/peptic-ulcer-drugs-market-2445) Industry. According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 30 to 40 percent of the U.S. population is affected by Helicobacter Pylori infection, which is a leading contributor to the development of peptic ulcers. With this substantial percentage of the population being at risk, the demand for effective peptic ulcer medications is expected to increase. Additionally, the growing awareness of gastrointestinal disorders, paired with targeted treatments from established pharmaceutical companies such as Pfizer and Takeda, is likely to elevate market performance. Advances in Research and Development for antibiotics and proton pump inhibitors are also pivotal in addressing this health issue, thus propelling the US Peptic Ulcer Drugs Market further. #### **Growing Geriatric Population** The aging population in the United States is another critical factor driving the US Peptic Ulcer Drugs Market Industry. The population over 65 years is projected to reach around 73 million by 2030, according to data from the U.S. Census Bureau. Older adults are more likely to experience gastrointestinal disorders, including peptic ulcers, due to factors like the use of anti-inflammatory medications and decreased mucosal defenses. Major biopharmaceutical companies, like AstraZeneca, actively focus on developing gastroprotective drugs specifically aimed at this demographic. Consequently, as this segment of the population expands, the demand for peptic ulcer treatments is expected to rise substantially. #### **Increased Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)** The escalating use of non-steroidal anti-inflammatory drugs (NSAIDs) among the U.S. population is increasingly recognized as a driver in the US Peptic Ulcer Drugs Market Industry. A report from the American Gastroenterological Association notes that upwards of 30 million Americans regularly use NSAIDs for pain relief. This widespread consumption raises the risk of gastrointestinal complications, including peptic ulcers, leading to heightened demand for preventive medications and treatments. Companies such as Johnson & Johnson and Novartis are investing in therapies focused on managing these side effects, ensuring they cater to the growing need for peptic ulcer medications associated with NSAID use. ### **US Peptic Ulcer Drugs Market Segment Insights** #### **Peptic Ulcer Drugs Market Pharmacological Class Insights** The US Peptic Ulcer Drugs Market, categorized by Pharmacological Class, presents a diverse landscape of treatment options aimed at managing and alleviating peptic ulcers. This market comprises several key classes, including Proton Pump Inhibitors (PPIs), Anti-histamines, H2 Antagonists, Antacids, and Others. Proton Pump Inhibitors, known for their efficacy in reducing stomach acid production, have emerged as a predominant choice among healthcare professionals and patients alike due to their strong and prolonged effect on acid-related diseases. Essentially, PPIs play a vital role in the treatment of peptic ulcers by promoting ulcer healing and preventing recurrence. Another noteworthy category within this segment is H2 Antagonists, which work by blocking histamine receptors in the stomach lining to reduce acid secretion. These medications represent a well-established therapeutic approach and continue to be widely used, especially for patients seeking effective management options that carry a favorable safety profile. Meanwhile, Antacids remain popular for their rapid action in neutralizing stomach acid, providing immediate relief for symptomatic patients. They serve as first-line therapy for those experiencing heartburn or indigestion, showcasing their importance in the spectrum of treatment options available. Additionally, the market includes various Anti-histamines that offer supportive roles in managing symptoms associated with peptic ulcers, particularly in patients experiencing concurrent gastroesophageal conditions. Other drug classes also contribute to the overall landscape, providing alternative treatment avenues for patients based on their unique clinical needs and preferences. This diversity in Pharmacological Class within the US Peptic Ulcer Drugs Market highlights not only the complex nature of peptic ulcer diseases but also the ongoing innovation and responsiveness of pharmaceutical companies to patient requirements and treatment guidelines. Market trends indicate a growing focus on personalized medicine and the development of novel formulations that enhance patient compliance and effectiveness. As awareness regarding peptic ulcers increases, driven by educational initiatives and healthcare provider recommendations, the demand for these pharmaceutical classes is likely to rise, offering opportunities for growth. Factors such as the increasing prevalence of ulcer-related conditions, advanced healthcare technologies, and enhanced access to medical care will further fuel market expansion over the coming years. In terms of challenges, the market faces competition from alternative treatments and patient preference for non-pharmacological approaches. However, ongoing Research and Development efforts continue to drive advancements in this sector, fostering innovative solutions aimed at improving patient outcomes and minimizing side effects. The segmentation of the US Peptic Ulcer Drugs Market by Pharmacological Class thus presents a robust overview of treatment options, reflecting the continuous evolution of therapeutic strategies tailored to address the needs of patients suffering from peptic ulcers. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review #### **Peptic Ulcer Drugs Market Clinical Insights** The Clinical segment of the US Peptic Ulcer Drugs Market is integral in addressing various forms of ulcers, including Gastric Ulcers, Duodenal Ulcers, and Esophageal Ulcers. Gastric Ulcers, known for their prevalence, are significant as they often result from chronic conditions like Helicobacter pylori infection and long-term use of certain medications. They require effective treatment strategies to prevent severe complications. Duodenal Ulcers, on the other hand, typically occur in the small intestine and represent a substantial portion of ulcer cases, making their management essential for public health. Esophageal Ulcers may arise due to acid reflux or other irritants, highlighting the importance of addressing both the symptoms and underlying causes. Given the rising incidence of these conditions, driven by factors such as lifestyle changes, dietary habits, and stress, the demand for effective peptic ulcer treatments in the US is significant. Understanding the dynamics within the Clinical segment helps stakeholders explore opportunities for innovation, particularly in developing tailored therapies to enhance patient outcomes, address recurrent issues, and ensure effective long-term management of these conditions. The overall trend in the market focuses on positive advancements in pharmacological options and patient adherence strategies, indicating promising avenues for growth in the peptic ulcer therapy landscape. ### **US Peptic Ulcer Drugs Market Key Players and Competitive Insights** The US Peptic Ulcer Drugs Market is characterized by intense competition, largely driven by the rising prevalence of peptic ulcer diseases and a growing focus on advanced therapeutics. The market comprises various players offering multiple drug classes including proton pump inhibitors, H2 receptor antagonists, and antibiotic therapies aimed at treating ulcers and their underlying causes. In recent years, significant investments in research and development have led to the emergence of innovative medications, which are frequently highlighted in the marketing strategies of major pharmaceutical companies. The competitive landscape is also shaped by regulatory changes and the demand for cost-effective treatment options, prompting companies to optimize their portfolios and strategically align their offerings to better cater to healthcare providers and patients alike. #### Merck and Co Merck and Co is a formidable player in the US Peptic Ulcer Drugs Market, with a strong focus on delivering high-quality therapeutic solutions that cater to the needs of patients suffering from peptic ulcers. The company has established a solid reputation for its commitment to research and development, driving the innovation of effective drugs that alleviate symptoms and contribute to the healing process. Merck's existing product portfolio demonstrates depth and efficacy, which has positively influenced its market presence. The company also benefits from a robust distribution network and strong relationships with healthcare professionals, allowing it to maintain a competitive edge. Continued investments in clinical trials and new research initiatives further solidify Merck's strengths in the market, helping it to expand its reach and influence in addressing peptic ulcer treatments. #### AstraZeneca AstraZeneca plays a significant role in the US Peptic Ulcer Drugs Market, bolstered by a suite of key products that address the various aspects of ulcer prevention and treatment. The company has successfully integrated a range of medications that are well-regarded for their effectiveness in managing peptic ulcers. AstraZeneca's market presence is enhanced by strategic alliances and partnerships that facilitate the development and distribution of innovative therapies. The firm has made notable strides through mergers and acquisitions, ensuring a diverse portfolio that can respond to varying market demands. Furthermore, AstraZeneca's emphasis on sustainability and corporate responsibility resonates well with the healthcare community, reinforcing its brand image. Overall, the company’s commitment to continual advancement in treatment options and patient care establishes its position as a strong competitor in the US Peptic Ulcer Drugs Market. #### Key Companies in the US Peptic Ulcer Drugs Market Include [Merck and Co](https://www.merckmanuals.com/home/quick-facts-digestive-disorders/gastritis-and-peptic-ulcer-disease/peptic-ulcer-disease#How-can-doctors-tell-if-I-have-a-peptic-ulcer?_v38064692) AstraZeneca GlaxoSmithKline BristolMyers Squibb Takeda Pharmaceuticals Sandoz Gilead Sciences Endo Pharmaceuticals Pfizer Sun Pharmaceutical Industries Amgen AbbVie Dr. Reddy's Laboratories Johnson and Johnson Mylan ### **US Peptic Ulcer Drugs Market Industry Developments** The US Peptic Ulcer Drugs Market has seen significant developments recently, with notable fluctuations in market valuations influenced by new drug approvals and therapeutic advancements. Companies like Merck and Co., AstraZeneca, GlaxoSmithKline, and Takeda Pharmaceuticals continue to innovate in the treatment space. Merck and Co. announced a strategic collaboration in April 2023 with a focus on Research and Development of novel therapeutic agents for gastrointestinal conditions, indicating a strong trend towards targeted therapies. Additionally, the acquisition landscape remains active, with Bristol-Myers Squibb reportedly completing a merger in June 2023 aimed at expanding its portfolio in gastrointestinal diseases, strengthening its market position. The presence of generics from companies like Sandoz and Mylan continues to impact pricing dynamics and access to treatment, creating competitive pressure on branded products. Over the past couple of years, the FDA has also accelerated the approval of new therapies, enhancing the treatment options available to patients. The increasing incidence of peptic ulcers in the US, fueled by lifestyle factors, continues to drive growth in this sector, indicating a robust and evolving market landscape that remains critical to patient care. ### **US Peptic Ulcer Drugs Market Segmentation Insights** #### **Peptic Ulcer Drugs Market Pharmacological Class Outlook** Proton Pump Inhibitors (PPIs) Anti-histamines H2 Antagonists Antacids Others #### **Peptic Ulcer Drugs Market Clinical Outlook** Gastric Ulcers Duodenal Ulcer Esophageal Ulcer ## Market Drivers ### Rising Healthcare Expenditure The upward trend in healthcare expenditure in the US is a significant driver for the peptic ulcer-drugs market. With healthcare spending projected to reach approximately $4.1 trillion by 2025, there is an increasing allocation of resources towards gastrointestinal health. This financial commitment enables healthcare providers to invest in advanced treatment options and medications for peptic ulcers. Additionally, insurance coverage for ulcer treatments is improving, making medications more affordable for patients. As a result, the demand for effective peptic ulcer therapies is likely to rise, contributing to the overall growth of the market. The correlation between healthcare expenditure and drug accessibility suggests a promising outlook for the peptic ulcer-drugs market. ### Advancements in Drug Formulations Innovations in drug formulations are significantly influencing the peptic ulcer-drugs market. The development of novel therapeutic agents, including targeted therapies and sustained-release formulations, enhances treatment efficacy and patient compliance. For instance, the introduction of new proton pump inhibitors (PPIs) and H2-receptor antagonists has expanded the treatment landscape. Market data indicates that the PPI segment alone accounts for over 50% of the total market share, reflecting the demand for effective ulcer management solutions. Additionally, the emergence of biosimilars and generic drugs is likely to provide cost-effective alternatives, making treatments more accessible to patients. As pharmaceutical companies invest in research and development, the introduction of advanced formulations is expected to bolster the peptic ulcer-drugs market. ### Growing Prevalence of Peptic Ulcers The rising incidence of peptic ulcers in the US is a primary driver for the peptic ulcer-drugs market. Factors such as increased stress levels, dietary habits, and the prevalence of Helicobacter pylori infections contribute to this trend. According to recent health statistics, approximately 4.5 million individuals in the US are diagnosed with peptic ulcers annually. This growing patient population necessitates effective treatment options, thereby propelling the demand for various drugs in the peptic ulcer-drugs market. Furthermore, the aging population, which is more susceptible to gastrointestinal disorders, is likely to increase the market size. As healthcare providers seek to address this issue, The emphasis on innovative drug formulations and therapies is expected to intensify, further driving market growth. ### Regulatory Support for Drug Approvals Regulatory support for the approval of new drugs is a crucial factor influencing the peptic ulcer-drugs market. The US Food and Drug Administration (FDA) has streamlined the drug approval process, facilitating quicker access to innovative treatments for peptic ulcers. This regulatory environment encourages pharmaceutical companies to invest in research and development, leading to the introduction of new therapies. Recent approvals of novel medications have expanded the treatment options available to healthcare providers and patients alike. As the regulatory landscape continues to evolve, it is expected that more effective and diverse treatment options will emerge, thereby enhancing the growth potential of the peptic ulcer-drugs market. ### Increasing Awareness of Gastrointestinal Health There is a notable increase in awareness regarding gastrointestinal health among the US population, which is positively impacting the peptic ulcer-drugs market. Educational campaigns and healthcare initiatives aimed at promoting digestive health have led to a greater understanding of peptic ulcers and their treatment options. This heightened awareness encourages individuals to seek medical advice and treatment, thereby increasing the demand for ulcer medications. Furthermore, the rise of digital health platforms and telemedicine has facilitated access to healthcare professionals, allowing patients to receive timely interventions. As awareness continues to grow, it is anticipated that more individuals will be diagnosed and treated for peptic ulcers, further driving the market. ## Future Outlook The [Peptic Ulcer Drugs Market](https://www.marketresearchfuture.com/reports/peptic-ulcer-drugs-market-2445) is projected to grow at a 4.22% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in drug formulations. **New opportunities:** - Development of personalized medicine for ulcer treatment - Expansion of telehealth services for patient consultations - Investment in AI-driven drug discovery platforms By 2035, the market is expected to achieve robust growth and innovation. ## Segment Insights ### By Pharmacological Class: Proton Pump Inhibitors (Largest) vs. Anti-histamines (Fastest-Growing) In the US peptic ulcer-drugs market, proton pump inhibitors (PPIs) continue to maintain the largest market share among the pharmacological classes. Their efficacy in reducing gastric acid secretion makes them a preferred choice for many healthcare providers and patients dealing with peptic ulcers. Anti-histamines, while holding a smaller market share, are recognized for their potential in treating ulcer-related symptoms and are gaining traction among specific patient demographics due to their accessibility and affordability. Growth trends for the pharmacological classes showcase a notable shift in preference towards anti-histamines, which are emerging as the fastest-growing category in the US peptic ulcer-drugs market. Factors driving this growth include increasing awareness of alternative treatment options, rising healthcare costs prompting patients to seek cost-effective solutions, and targeted advertising that highlights the benefits of anti-histamines. Furthermore, the ongoing research and development efforts to enhance the efficacy of these drugs are expected to boost their market presence even further. Proton Pump Inhibitors (Dominant) vs. Anti-histamines (Emerging) Proton pump inhibitors remain the dominant force in the pharmacological classes used to manage peptic ulcers, primarily due to their proven effectiveness and favorable therapeutic profiles. They provide long-lasting relief from symptoms by significantly reducing gastric acid production, which is crucial for ulcer healing. On the other hand, anti-histamines represent an emerging category that is gaining momentum in the market. Their mechanism of action targets histamine receptors to alleviate discomfort associated with ulcers. The affordability and easy availability of anti-histamines are appealing to consumers, and their increasing endorsement by healthcare professionals could position them as serious competitors in the market. This dynamic is reshaping the landscape of treatment options available to patients. ### By Clinical: Gastric ulcers (Largest) vs. Duodenal ulcers (Fastest-Growing) In the US peptic ulcer-drugs market, gastric ulcers represent the largest segment, holding a significant share among the various types of ulcers being treated. While duodenal ulcers are also considerable, their market presence is rapidly increasing, indicating changing preferences in treatment approaches. Esophageal ulcers, though important, hold a smaller market share, primarily driven by specific chronic conditions that target esophageal health. The growth trends in the clinical segment suggest increasing investments in research for innovative treatment solutions for gastric ulcers, along with a surge in demand for effective therapies for duodenal ulcers, which are becoming recognized for their rising incidence. Esophageal ulcers remain steady but rely on advancements in surgical techniques and supportive therapies. Overall, the segment is positioned for sustained growth with ongoing clinical developments and patient awareness campaigns. Gastric ulcers (Dominant) vs. Duodenal ulcers (Emerging) Gastric ulcers are characterized by their shared symptomology with other digestive issues but remain dominant due to their established treatment protocols and consistent patient management strategies. The medications for gastric ulcers have received robust support from clinical guidelines, ensuring that they remain a staple in treatment regimens. On the other hand, duodenal ulcers are emerging significantly in the market, propelled by heightened awareness and a focus on gastrointestinal health. They often require different therapeutic approaches, which are evolving to include more efficient and targeted treatments. This emerging segment is gaining attention for its potential market growth fueled by increasing healthcare spending and improvements in diagnostic technologies. ## Competitive Benchmarking The peptic ulcer-drugs market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Pfizer Inc (US), AstraZeneca PLC (GB), and Takeda Pharmaceutical Company Limited (JP) are actively engaged in enhancing their product portfolios and expanding their market reach. Pfizer Inc (US) has been particularly focused on leveraging its research capabilities to develop novel therapies, while AstraZeneca PLC (GB) emphasizes strategic collaborations to enhance its drug development pipeline. Takeda Pharmaceutical Company Limited (JP) is also investing in digital health initiatives, which reflects a broader trend towards integrating technology into treatment solutions. Collectively, these strategies contribute to a dynamic competitive environment where innovation and collaboration are paramount.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market's competitive structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of therapeutic options, yet it also necessitates that companies differentiate themselves through unique value propositions and operational excellence. In October Pfizer Inc (US) announced a strategic partnership with a leading digital health company to develop a mobile application aimed at improving patient adherence to peptic ulcer treatments. This initiative is significant as it not only enhances patient engagement but also positions Pfizer at the forefront of digital health integration, potentially leading to improved treatment outcomes and customer loyalty. In September AstraZeneca PLC (GB) launched a new formulation of its existing peptic ulcer medication, which is designed to provide faster relief and improved patient compliance. This product innovation is crucial as it addresses unmet needs in the market, thereby strengthening AstraZeneca's competitive position and expanding its market share. In August Takeda Pharmaceutical Company Limited (JP) expanded its research and development facilities in the US, focusing on the discovery of new therapeutic agents for gastrointestinal disorders. This expansion underscores Takeda's commitment to innovation and its strategic intent to enhance its R&D capabilities, which may lead to the introduction of groundbreaking therapies in the peptic ulcer segment. As of November the competitive trends in the peptic ulcer-drugs market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, allowing companies to pool resources and expertise to accelerate innovation. Looking ahead, it is likely that competitive differentiation will evolve from traditional price-based strategies to a focus on technological advancements, innovative treatment solutions, and robust supply chain management. This shift may ultimately redefine how companies compete, emphasizing the importance of agility and responsiveness in meeting patient needs. ## Recent News & Developments The US Peptic Ulcer Drugs Market has seen significant developments recently, with notable fluctuations in market valuations influenced by new drug approvals and therapeutic advancements. Companies like Merck and Co., AstraZeneca, GlaxoSmithKline, and Takeda Pharmaceuticals continue to innovate in the treatment space. Merck and Co. announced a strategic collaboration in April 2023 with a focus on Research and Development of novel therapeutic agents for gastrointestinal conditions, indicating a strong trend towards targeted therapies. Additionally, the acquisition landscape remains active, with Bristol-Myers Squibb reportedly completing a merger in June 2023 aimed at expanding its portfolio in gastrointestinal diseases, strengthening its market position. The presence of generics from companies like Sandoz and Mylan continues to impact pricing dynamics and access to treatment, creating competitive pressure on branded products. Over the past couple of years, the FDA has also accelerated the approval of new therapies, enhancing the treatment options available to patients. The increasing incidence of peptic ulcers in the US, fueled by lifestyle factors, continues to drive growth in this sector, indicating a robust and evolving market landscape that remains critical to patient care. ## Report Scope | MARKET SIZE 2024 | 1130.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1177.69(USD Million) | | MARKET SIZE 2035 | 1780.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.22% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer Inc (US), AstraZeneca PLC (GB), Boehringer Ingelheim GmbH (DE), Takeda Pharmaceutical Company Limited (JP), Novartis AG (CH), GlaxoSmithKline PLC (GB), Sanofi S.A. (FR), AbbVie Inc (US) | | Segments Covered | Pharmacological Class, Clinical | | Key Market Opportunities | Emerging therapies targeting resistant peptic ulcer strains present a notable opportunity in the peptic ulcer-drugs market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the peptic ulcer-drugs market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US peptic ulcer-drugs market in 2024?** A: The overall market valuation was $1130.0 Million in 2024. **Q: What is the projected market valuation for the US peptic ulcer-drugs market by 2035?** A: The projected valuation for 2035 is $1780.0 Million. **Q: What is the expected CAGR for the US peptic ulcer-drugs market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 4.22%. **Q: Which pharmacological class had the highest valuation in the US peptic ulcer-drugs market in 2024?** A: Proton pump inhibitors (PPIs) had the highest valuation at $450.0 Million to $700.0 Million. **Q: What is the valuation range for anti-histamines in the US peptic ulcer-drugs market?** A: The valuation range for anti-histamines is $200.0 Million to $300.0 Million. **Q: How do gastric ulcers compare to duodenal ulcers in terms of market valuation in 2024?** A: Gastric ulcers had a valuation range of $450.0 Million to $700.0 Million, while duodenal ulcers ranged from $350.0 Million to $550.0 Million. **Q: Which companies are considered key players in the US peptic ulcer-drugs market?** A: Key players include Pfizer Inc, AstraZeneca PLC, Boehringer Ingelheim GmbH, and others. **Q: What is the valuation range for H2 antagonists in the US peptic ulcer-drugs market?** A: The valuation range for H2 antagonists is $250.0 Million to $400.0 Million. **Q: What is the market valuation for esophageal ulcers in the US peptic ulcer-drugs market?** A: The market valuation for esophageal ulcers ranges from $330.0 Million to $530.0 Million. **Q: What is the valuation range for antacids in the US peptic ulcer-drugs market?** A: The valuation range for antacids is $150.0 Million to $250.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-peptic-ulcer-drugs-market-19500*